


Pregnancy outcome following exposure to vaginal fenticonazole in pregnancy: a case report

Michael Ceulemans^{1,2}, Pauline Dreesen³, Wilfried Gyselaers³

¹Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; ²Research Foundation Flanders (FWO), Belgium; ³UHasselt, Belgium.

Background and Objectives



Fenticonazole is an imidazole antifungal medication used to treat **vaginal candidiasis**, which is common during pregnancy.


However, **safety data** of vaginal fenticonazole **in pregnancy** are lacking.



The objective of this **case report** was to describe the pregnancy and neonatal outcomes following maternal use of vaginal fenticonazole during pregnancy.

Methods

The case was derived from the PREMOM II multicenter, prospective, randomized controlled clinical trial in Belgium. During pregnancy, the woman was **exposed three times** to vaginal **fenticonazole** (600mg ovule at 17 weeks and twice to vaginal fenticonazole cream later in pregnancy).



Outcome data were extracted from the electronic patient file after delivery. The study received ethical approval (BE300201938651); patient consent was obtained.

Conclusion

This study provided the **first case report** following **maternal exposure** to **vaginal fenticonazole** during the second and third pregnancy trimester.

Results



Patient characteristics

25-year-old Caucasian woman
Pre-pregnancy BMI 26.2 kg/m²
Pre-existing hypertension
Type 1 diabetes
History of psychiatric disorders
Two prior pregnancies

Index pregnancy

Singleton
Spontaneous pregnancy
3 cigarettes/day (entire pregnancy)

Complicated with

Uncontrolled diabetes
Preterm contractions
Polyhydramnios
Macrosomia
⇒ Hospitalization at 32w6d
Gestational hypertension from 35w

Neonatal outcomes

Spontaneous vaginal delivery at 36w2d
Female neonate
Birth weight 4085g
Apgar score = 7 (at 1min)
Apgar score = 8 (at 5min)

| Maternal medication use during pregnancy | Timing of exposure |
|--|--|
| Insulins | Entire pregnancy |
| Low-dose aspirin (160mg/day) | 13w6d – 36w |
| Labetalol (300-600mg/day) | 35w until delivery |
| Atosiban | 32w6d – 33w |
| Betamethasone | 32w6d – 33w |
| Folic acid (4mg) | 7w5d – 24w3d |
| Cranberry and D-mannose | 32w6d – 35w5d |
| Vaginal fenticonazole: 600mg ovule cream | 17w 23w6d – 24w5d 35w5d – delivery |

Acknowledgements

The research activities of Michael Ceulemans and Pauline Dreesen are supported by a Senior Postdoctoral Fellowship of the Resesarch Foundation Flanders (FWO, 1246425N) and Hasselt University (LCRC and BOF), respectively. This poster was created with the help of Elise Van den Broeck.

Contact Information

Michael Ceulemans, PharmD, PhD | michael.ceulemans@kuleuven.be
Campus Gasthuisberg, O&N2 Herestraat 49 box 521, 3000 Leuven, Belgium